Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan;
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Anticancer Res. 2021 Mar;41(3):1655-1662. doi: 10.21873/anticanres.14928.
BACKGROUND/AIM: Our previous study revealed the association between extracellular water-to-total body water ratio (ECW/TBW) and the therapeutic durability of chemotherapy and/or immune checkpoint inhibitors in advanced lung cancer. We retrospectively examined the usefulness of ECW/TBW in detecting frailty compared to other bioelectrical impedance (BIA) parameters in a larger number of patients.
Lung cancer patients underwent BIA before anti-cancer therapy at our hospital between June 1, 2018 and July 31, 2020.
Of 99 patients, 26 were assigned to ECW/TBW≥0.4 (higher group: HG) and 57 to ECW/TBW<0.4 (lower group: LG). ECW/TBW increased significantly with performance deterioration and ageing. HG patients had significantly shorter time-to-treatment failure (TTF) than LG patients. In patients with performance status 0-1, those in the HG had shorter TTF than those in the LG. ECW/TBW was the only independent predictor of TTF according to multivariate analysis.
ECW/TBW is an objective biomarker for detecting frailty among lung cancer patients.
背景/目的：我们之前的研究表明，细胞外液与总体水比值（ECW/TBW）与晚期肺癌患者化疗和/或免疫检查点抑制剂治疗的耐久性有关。我们回顾性地检查了在更多患者中，与其他生物电阻抗（BIA）参数相比，ECW/TBW 在检测脆弱性方面的有用性。
2018 年 6 月 1 日至 2020 年 7 月 31 日，在我院接受抗癌治疗前，肺癌患者接受了 BIA。
在 99 名患者中，26 名患者被分配到 ECW/TBW≥0.4（高组：HG），57 名患者被分配到 ECW/TBW<0.4（低组：LG）。ECW/TBW 随着身体机能恶化和年龄增长而显著增加。HG 患者的治疗失败时间（TTF）明显短于 LG 患者。在体能状态为 0-1 的患者中，HG 患者的 TTF 短于 LG 患者。根据多变量分析，ECW/TBW 是 TTF 的唯一独立预测因子。
ECW/TBW 是检测肺癌患者脆弱性的一种客观生物标志物。
